Arcturus Therapeutics Holdings Inc.
ARCTNext catalyst
ARCT-032
Cystic Fibrosis
Get an email about ARCT's next catalysts
Track Arcturus Therapeutics Holdings (ARCT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
ARCT Earnings Report
EPS Est: $-0.60 | FQ end Sep/2026 | Call: amc
ARCT-032 Phase 2 Est. Readout (LunairCF)
Primary completion for ARCT-032 trial (NCT06747858) in Cystic Fibrosis
SourceMarket Overview
Stock performance and key metrics
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
WebsiteInfluenza vaccine, adjuvanted
COVID-19
ARCT-2303
COVID-19
ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
COVID-19 Vaccines
ARCT-165
COVID-19
ARCT-021 Dose 1
SARS-CoV-2
ARCT-021 Dose 4
SARS-CoV-2
ARCT-021
COVID-19
ARCT-021 Dose 2
SARS-CoV-2
ARCT-021 Dose Regimen 2
SARS-CoV-2
ARCT-021 Dose Regimen 1
SARS-CoV-2
ARCT-021 Dose 3
SARS-CoV-2
ARCT-810
OTC Deficiency
ARCT-154
COVID-19
ARCT-032
Cystic Fibrosis
ARCT-2304
Influenza, Human
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Influenza vaccine, adjuvanted | Phase 3 | COVID-19 | - | - |
ARCT-2303 | Phase 3 | COVID-19 | - | - |
ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine | Phase 3 | COVID-19 Vaccines | - | - |
ARCT-165 | Phase 2 | COVID-19 | - | - |
ARCT-021 Dose 1 | Phase 2 | SARS-CoV-2 | - | - |
ARCT-021 Dose 4 | Phase 2 | SARS-CoV-2 | - | - |
ARCT-021 | Phase 2 | COVID-19 | - | - |
ARCT-021 Dose 2 | Phase 2 | SARS-CoV-2 | - | - |
ARCT-021 Dose Regimen 2 | Phase 2 | SARS-CoV-2 | - | - |
ARCT-021 Dose Regimen 1 | Phase 2 | SARS-CoV-2 | - | - |
ARCT-021 Dose 3 | Phase 2 | SARS-CoV-2 | - | - |
ARCT-810 | Phase 2 | OTC Deficiency | - | - |
ARCT-154 | Phase 2 | COVID-19 | - | - |
ARCT-032 | Phase 2 | Cystic Fibrosis | - | - |
ARCT-2304 | Phase 2 | Influenza, Human | - | - |
Frequently asked questions
What is in Arcturus Therapeutics Holdings Inc.'s drug pipeline?→
CatalystAlert tracks 15 drug candidates in Arcturus Therapeutics Holdings Inc.'s (ARCT) pipeline across Phase 3, Phase 2. Its lead program is ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arcturus Therapeutics Holdings Inc.'s next FDA catalyst?→
Arcturus Therapeutics Holdings Inc.'s (ARCT) next tracked catalyst is a Phase 2 readout expected June 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARCT biotech catalysts?→
Add ARCT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arcturus Therapeutics Holdings Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.